Rallybio Corporation (RLYB)Healthcare | Biotechnology | New Haven, United States | NasdaqCM
16.72 USD
-0.06
(-0.358%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:28 a.m. EDT
The immediate catalyst here is the announced merger agreement, which has temporarily halted the stock's catastrophic decline and pushed it toward a two-year high. However, the underlying business fundamentals remain severely impaired, characterized by massive losses, negative operating cash flow, and a complete lack of profitability. The price history tells a stark story of destruction, with the asset losing nearly 97% of its value over the last four years, driven by four consecutive years of double-digit annual declines. While the merger offers a potential path to survival or restructuring, the current entity represents a deep value trap with no intrinsic earnings power. Consequently, there is no reliable income stream to offer investors, and the long-term outlook remains bleak until the combined entity proves it can generate sustainable cash flow. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.014302 |
| MSTL | 0.021704 |
| AutoARIMA | 0.023275 |
| AutoETS | 0.023445 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.219 |
| Excess Kurtosis | -0.70 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.114 |
| Market Cap | 88,826,400 |
| Trailing P/E | 2.09 |
| Forward P/E | -3.10 |
| Beta | -0.71 |
| Profit Margins | 7051.24% |
| Website | https://www.rallybio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.922897 |
| Address1 | 234 Church Street |
| All Time High | 206.24 |
| All Time Low | 1.76 |
| Ask | 22.04 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 7,250 |
| Average Daily Volume3 Month | 19,143 |
| Average Volume | 19,143 |
| Average Volume10Days | 7,250 |
| Beta | -0.714 |
| Bid | 12.06 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 17.806 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.72 |
| Current Ratio | 27.265 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 16.85 |
| Day Low | 16.69 |
| Display Name | Rallybio |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -25,380,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.16 |
| Enterprise To Revenue | -6.281 |
| Enterprise Value | -4,057,456 |
| Eps Current Year | -5.52 |
| Eps Forward | -5.4 |
| Eps Trailing Twelve Months | 8.01 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.7964 |
| Fifty Day Average Change | -0.07640076 |
| Fifty Day Average Change Percent | -0.0045486386 |
| Fifty Two Week Change Percent | 292.2897 |
| Fifty Two Week High | 17.574 |
| Fifty Two Week High Change | -0.8540001 |
| Fifty Two Week High Change Percent | -0.048594523 |
| Fifty Two Week Low | 3.67 |
| Fifty Two Week Low Change | 13.049999 |
| Fifty Two Week Low Change Percent | 3.5558581 |
| Fifty Two Week Range | 3.67 - 17.574 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,565,400,000 |
| Float Shares | 1,720,495 |
| Forward Eps | -5.4 |
| Forward P E | -3.096296 |
| Free Cashflow | -14,290,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Fullday Change | -0.060001373 |
| Fullday Change Percent | -0.3575767 |
| Fullday Price | 16.72 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -9,181,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24537 |
| Held Percent Institutions | 0.86140996 |
| Implied Shares Outstanding | 5,312,584 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,770,336,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. |
| Long Name | Rallybio Corporation |
| Market | us_market |
| Market Cap | 88,826,400 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1673028342 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 45,551,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 89,570,166 |
| Open | 16.69 |
| Operating Cashflow | 26,712,000 |
| Operating Margins | -39.35449 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 203 859 3820 |
| Previous Close | 16.78 |
| Price Eps Current Year | -3.0289855 |
| Price Hint | 2 |
| Price To Book | 0.9390093 |
| Price To Sales Trailing12 Months | 137.50217 |
| Profit Margins | 70.512375 |
| Quick Ratio | 26.03 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.060001373 |
| Regular Market Change Percent | -0.3575767 |
| Regular Market Day High | 16.85 |
| Regular Market Day Low | 16.69 |
| Regular Market Day Range | 16.69 - 16.85 |
| Regular Market Open | 16.69 |
| Regular Market Previous Close | 16.78 |
| Regular Market Price | 16.72 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 4,966 |
| Return On Assets | -0.21319 |
| Return On Equity | 0.6486 |
| Revenue Per Share | 0.114 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 5,312,584 |
| Shares Percent Shares Out | 0.0093 |
| Shares Short | 49,245 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 54,943 |
| Short Name | Rallybio Corporation |
| Short Percent Of Float | 0.0111 |
| Short Ratio | 4.52 |
| Source Interval | 15 |
| State | CT |
| Symbol | RLYB |
| Total Cash | 92,849,000 |
| Total Cash Per Share | 17.484 |
| Total Debt | 0 |
| Total Revenue | 646,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 8.01 |
| Trailing P E | 2.0873907 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.18197 |
| Two Hundred Day Average Change | 4.5380297 |
| Two Hundred Day Average Change Percent | 0.37252018 |
| Type Disp | Equity |
| Volume | 4,966 |
| Website | https://www.rallybio.com |
| Zip | 6,510 |